Aim’s struggles in 2023 have again been thrown into harsher relief by the relative resilience of the UK’s FTSE 100 index.
Dismaying as this may be for investors, it’s par for the course at a time of tighter monetary policy and an uncertain economic outlook. All the same, the Aim 100 index of high-growth stocks has developed some superficial attributes more in keeping with the kind of ‘old world’ moniker that’s usually applied to the FTSE 100.
Aim weightings to both tech and healthcare (typically biotechs) have fallen back this year, by about three percentage points apiece, while allocations to financials have risen from 9 to 14 per cent and the industrials weighting has nudged up, too.